NANTES, FRANCE--(Marketwire - June 15, 2010) -
| Highlighted Links |
companynewsgroup Home Page |
Terms of the agreement were not disclosed
"We are very pleased to convert another research license into a new commercial agreement within the animal vaccine field, increasing penetration of the EB66® cell line in this fast developing market. This new license again confirms that the EB66® cell platform is a reference cell substrate for the industrial manufacture of viral vaccines. It also confirms our analysis that an increasing number of vaccine companies are moving away from chicken eggs to adopt the EB66® cell platform as their standard production platform. With many advanced discussions with pharmaceutical and biotechnology companies both for vaccine and protein productions, we are confident that 2010 will be another dynamic year for EB66® licensing with the renewed objective to sign 7 new licenses this year of which 2 commercial licenses", said Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS.
**********************
Next financial press release:
21 July 2010, after NYSE Euronext market closing: Second quarter 2010 revenues
About the EB66® cell line
The EB66® cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics, such as long-term genetic stability, immortality and cell growth up to high cell densities in suspension in a serum-free medium ( > 40 millions cells/mL).
The BMF (Biologics Master File) for the registration of the EB66® cell line with the FDA (U.S. Food and Drug Administration) was filed on June 27, 2008.
The EB66® cells replicate a wide range of human and animal viruses and are currently used or being evaluated for the production of viral vaccines by the major players in vaccines.
The EB66® cells are easily genetically engineered to efficiently express recombinant proteins of interest ( > 1 g/l). Monoclonal antibodies produced in EB66® cells have human-like glycosylation profile, with the remarkable additional feature of having reduced fucose content. This latter characteristic provides a better cytotoxic activity to antibodies, particularly useful in the treatment of cancer cells.
About VIVALIS (www.vivalis.com)
VIVALIS (Euronext code: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:
1. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines and monoclonal antibodies. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.
2. Through the Humalex® platform, VIVALIS proposes customers solutions for the generation, development and production of human antibodies. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).
Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (ca. 1,500 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters.
+-------------------------+-+ |VIVALIS | | +-------------------------+-+ |Listed on Euronext Paris | | |– Compartment C of NYSE | | |Euronext | | +-------------------------+-+ |Reuters: VLS.PA – | | |Bloomberg: VLS FP | | +-------------------------+-+ |Included in NYSE | | |Euronext’s SBF 250, CAC | | |Small 90 and Next Biotech| | |indexes | | +-------------------------+-+ +-------------------------+-+ Contacts VIVALIS Franck Grimaud, CEO Email: investors@vivalis.com NewCap Financial communications agency Steve Grobet / Pierre Laurent Tel.: +33 (0) 1 44 71 94 91 Email: vivalis@newcap.fr
This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including the risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.
This information is provided by HUGIN
